DHEA inhibited WNT signaling via downregulation of active β-catenin in the nucleus, thereby decreasing the transcriptional activity of downstream target genes, such as CD44 and CCND1 in HNSCC (Figure 2). The gene discussed is CD44; the disease is head and neck squamous cell carcinoma.